PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.01
Dangerously higher D/E above 1.5x CRVO's 0.00. Jim Chanos would check for potential debt spiral risks.
13.65
Much higher net debt at 1.25-1.5x CRVO's 9.98. Bill Ackman would demand clear deleveraging catalysts.
No Data
No Data available this quarter, please select a different quarter.
17.71
Current ratio 75-90% of CRVO's 22.39. Bruce Berkowitz would look for working capital optimization opportunities.
No Data
No Data available this quarter, please select a different quarter.